Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 8 No. 6, June 2007
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinhorn, R. H.
Right arrow Articles by Kinsella, J. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Steinhorn, R. H.
Right arrow Articles by Kinsella, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

NeoReviews Vol.8 No.6 2007 e247
© 2007 American Academy of Pediatrics

Pharmacology Review

Use of Inhaled Nitric Oxide in the Preterm Infant

Robin H. Steinhorn, MD*
John P. Kinsella, MD{dagger}

* Children's Memorial Hospital and Northwestern University, Chicago, Ill
{dagger} The Children's Hospital and University of Colorado School of Medicine, Denver, Colo

Studies have shown that inhaled nitric oxide (iNO) improves ventilation/perfusion matching, decreases lung inflammation and oxidant stress, and restores more normal patterns of angiogenesis and parenchymal growth in the immature lung. Such findings suggest a potential role for this therapy in preterm newborns at risk for bronchopulmonary dysplasia. Early clinical trials have shown that iNO can benefit larger preterm infants (>1,000 g) who have early respiratory failure and preterm infants who continue to require positive pressure support after the first postnatal week. Debate continues as to whether iNO increases the rate of intracerebral hemorrhage. Additional trials are needed to discern benefits to specific forms and durations of iNO therapy in both the short and long term.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Academy of Pediatrics.